Advertisement admin, Author at Pharmaceutical Business review - Page 411 of 458
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by Lavillcok Lavillcok

Gilead Sciences commences HIV drug trial

GS-7340 is a nucleotide reverse transcriptase inhibitor (NtRTI) similar to the company’s HIV drug Viread. The double-blind 48-week clinical trial will include150 patients, who are randomized (2:1) to

Granules-Omnichem to start production in 2013

According to the Goodreturns, the joint-venture will provide high value active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. The construction of the facility will start by November

Amerinet deploys GHX procure-to-pay solutions

As per the agreement, Amerinet’s members will have access to services including item master management, contract and price management, requisitioning and workflow control, as well as invoice automation.